With the general run on pharma products in Australia (and I'm making a big assumption this will hold true across western economies), is there likely to be a negative impact on PAL's outlook as a business?
Ann: Palla Pharma Investor Presentation - FY19 Results & Outlook, page-20
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)